BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Barrenäs F, Hansen SG, Law L, Driscoll C, Green RR, Smith E, Chang J, Golez I, Urion T, Peng X, Whitmore L, Newhouse D, Hughes CM, Morrow D, Randall KT, Selseth AN, Ford JC, Gilbride RM, Randall BE, Ainslie E, Oswald K, Shoemaker R, Fast R, Bosche WJ, Axthelm MK, Fukazawa Y, Pavlakis GN, Felber BK, Fourati S, Sekaly RP, Lifson JD, Komorowski J, Kosmider E, Shao D, Song W, Edlefsen PT, Picker LJ, Gale M Jr. Interleukin-15 response signature predicts RhCMV/SIV vaccine efficacy. PLoS Pathog 2021;17:e1009278. [PMID: 34228762 DOI: 10.1371/journal.ppat.1009278] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Malouli D, Gilbride RM, Wu HL, Hwang JM, Maier N, Hughes CM, Newhouse D, Morrow D, Ventura AB, Law L, Tisoncik-Go J, Whitmore L, Smith E, Golez I, Chang J, Reed JS, Waytashek C, Weber W, Taher H, Uebelhoer LS, Womack JL, McArdle MR, Gao J, Papen CR, Lifson JD, Burwitz BJ, Axthelm MK, Smedley J, Früh K, Gale M Jr, Picker LJ, Hansen SG, Sacha JB. Cytomegalovirus-vaccine-induced unconventional T cell priming and control of SIV replication is conserved between primate species. Cell Host Microbe 2022:S1931-3128(22)00359-6. [PMID: 35981532 DOI: 10.1016/j.chom.2022.07.013] [Reference Citation Analysis]
2 Hansen SG, Hancock MH, Malouli D, Marshall EE, Hughes CM, Randall KT, Morrow D, Ford JC, Gilbride RM, Selseth AN, Trethewy RE, Bishop LM, Oswald K, Shoemaker R, Berkemeier B, Bosche WJ, Hull M, Silipino L, Nekorchuk M, Busman-Sahay K, Estes JD, Axthelm MK, Smedley J, Shao D, Edlefsen PT, Lifson JD, Früh K, Nelson JA, Picker LJ. Myeloid cell tropism enables MHC-E-restricted CD8+ T cell priming and vaccine efficacy by the RhCMV/SIV vaccine. Sci Immunol 2022;7:eabn9301. [PMID: 35714200 DOI: 10.1126/sciimmunol.abn9301] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
3 Conlon K, Watson DC, Waldmann TA, Valentin A, Bergamaschi C, Felber BK, Peer CJ, Figg WD, Potter EL, Roederer M, McNeel DG, Thompson JA, Gupta S, Leidner R, Wang-Gillam A, Parikh NS, Long D, Kurtulus S, Ho Lee L, Chowdhury NR, Bender F, Pavlakis GN. Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors. J Immunother Cancer 2021;9:e003388. [PMID: 34799399 DOI: 10.1136/jitc-2021-003388] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
4 D'Souza MP, Palin AC, Calder T, Golding H, Kleinstein SH, Milliken EL, O'Connor D, Tomaras G, Warren J, Boggiano C. Mind the gap from research laboratory to clinic: Challenges and opportunities for next-generation assays in human diseases. Vaccine 2021;39:5233-9. [PMID: 34366145 DOI: 10.1016/j.vaccine.2021.07.071] [Reference Citation Analysis]
5 Méndez-Lagares G, Chin N, Chang WLW, Lee J, Rosás-Umbert M, Kieu HT, Merriam D, Lu W, Kim S, Adamson L, Brander C, Luciw PA, Barry PA, Hartigan-O'Connor DJ. Cytomegalovirus mediates expansion of IL-15-responsive innate-memory cells with SIV killing function. J Clin Invest 2021;131:148542. [PMID: 34153005 DOI: 10.1172/JCI148542] [Cited by in F6Publishing: 2] [Reference Citation Analysis]